Literature DB >> 17019367

Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings.

David M Moore1, Jonathan Mermin, Anna Awor, Benita Yip, Robert S Hogg, Julio S G Montaner.   

Abstract

BACKGROUND: World Health Organization (WHO) guidelines for the use of antiretroviral therapy (ART) in resource-limited settings state that CD4 cell counts may be used to indicate when ART regimens should be changed because of treatment failure. The performance of immunologic monitoring for this purpose has not been evaluated, however.
METHODS: Participants aged > or =18 years from the British Columbia HIV/AIDS Drug Treatment Program who had CD4 cell counts < or =200 cells/microL or an AIDS diagnosis at baseline had CD4 cell counts measured at 6 and 12 months after treatment initiation. Logistic regression analysis was used to calculate sensitivity, specificity, and positive and negative predictive values for immunologic responses in terms of predicting failure to achieve 2 viral load measurements < 500 copies/mL within 1 year.
RESULTS: Viral load suppression occurred in 674 (60%) of 1125 subjects. Using no increase in CD4 cell counts at 6 months as a definition of treatment failure had a sensitivity of 34%, specificity of 94%, positive predictive value of 75%, and negative predictive value of 71% for predicting failure to achieve virologic suppression. Using 12-month CD4 cell count values, the measurements were 35%, 95%, 79%, and 73%, respectively.
CONCLUSION: Immunologic criteria to predict which patients have not achieved virologic suppression results in significant misclassification of therapeutic responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17019367     DOI: 10.1097/01.qai.0000243105.80393.42

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  38 in total

1.  Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.

Authors:  Holly E Rawizza; Beth Chaplin; Seema T Meloni; Geoffrey Eisen; Tara Rao; Jean-Louis Sankalé; Abdoulaye Dieng-Sarr; Oche Agbaji; Daniel I Onwujekwe; Wadzani Gashau; Reuben Nkado; Ernest Ekong; Prosper Okonkwo; Robert L Murphy; Phyllis J Kanki
Journal:  Clin Infect Dis       Date:  2011-12       Impact factor: 9.079

2.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.

Authors:  Rami Kantor; Lameck Diero; Allison Delong; Lydia Kamle; Sarah Muyonga; Fidelis Mambo; Eunice Walumbe; Wilfred Emonyi; Philip Chan; E Jane Carter; Joseph Hogan; Nathan Buziba
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

3.  Comparison of the Abbott m2000 HIV-1 Real-Time and Roche AMPLICOR Monitor v1.5 HIV-1 assays on plasma specimens from Rakai, Uganda.

Authors:  I Ssebugenyi; A Kizza; B Mpoza; G Aluma; I Boaz; K Newell; O Laeyendecker; J P Shott; D Serwadda; S J Reynolds
Journal:  Int J STD AIDS       Date:  2011-07       Impact factor: 1.359

4.  Mortality after failure of antiretroviral therapy in sub-Saharan Africa.

Authors:  Olivia Keiser; Hannock Tweya; Paula Braitstein; François Dabis; Patrick MacPhail; Andrew Boulle; Denis Nash; Robin Wood; Ruedi Lüthi; Martin W G Brinkhof; Mauro Schechter; Matthias Egger
Journal:  Trop Med Int Health       Date:  2009-12-09       Impact factor: 2.622

5.  Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.

Authors:  Susanne May; Anthony Gamst; Richard Haubrich; Constance Benson; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

6.  Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.

Authors:  Eugène Messou; Delphine Gabillard; Raoul Moh; André Inwoley; Souleymane Sorho; Serge Eholié; François Rouet; Catherine Seyler; Christine Danel; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

7.  A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.

Authors:  Steven J Reynolds; Cissy Kityo; Claire W Hallahan; Geoffrey Kabuye; Diana Atwiine; Frank Mbamanya; Francis Ssali; Robin Dewar; Marybeth Daucher; Richard T Davey; Peter Mugyenyi; Anthony S Fauci; Thomas C Quinn; Mark R Dybul
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

8.  Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

Authors:  Mattia C F Prosperi; Michal Rosen-Zvi; André Altmann; Maurizio Zazzi; Simona Di Giambenedetto; Rolf Kaiser; Eugen Schülter; Daniel Struck; Peter Sloot; David A van de Vijver; Anne-Mieke Vandamme; Anders Sönnerborg
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy.

Authors:  Olivia Keiser; Patrick MacPhail; Andrew Boulle; Robin Wood; Mauro Schechter; François Dabis; Eduardo Sprinz; Matthias Egger
Journal:  Trop Med Int Health       Date:  2009-07-14       Impact factor: 2.622

10.  Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay.

Authors:  Sumathi Sivapalasingam; Beatrice Wangechi; Fatuma Marshed; Maura Laverty; Shaffiq Essajee; Robert S Holzman; Fred Valentine
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.